玻璃体腔注药治疗视网膜静脉阻塞继发黄斑水肿研究进展  

Research Progress on Intravitreal Injection Therapy for Macular Edema Secondary to Retinal Vein Occlusion

作　　者：邓垚 于兰 

机构地区：[1]吉首大学医学院,湖南 吉首 [2]吉首大学第四临床学院,湖南 怀化

出　　处：《临床医学进展》2024年第11期1263-1271,共9页Advances in Clinical Medicine

摘　　要：视网膜静脉阻塞(RVO)是临床常见的视网膜血管病,而RVO发生后常继发黄斑水肿(ME)。玻璃体腔注射是治疗RVO-ME的有效且安全的一种给药方式。目前随着医学的进展,用于玻璃体腔注射治疗该种疾病的药物越来越多,主要为糖皮质激素类药物和抗VEGF药物,糖皮质激素包括有曲安奈德、地塞米松、醋酸氟轻松,抗VEGF药物主要有雷珠单抗、贝伐单抗、阿柏西普、康柏西普等。本文将对这些药物在RVO-ME中的治疗进展作综述,以供医疗实践中作参考。Retinal vein occlusion (RVO) is a prevalent retinal vascular disease, which often leads to secondary macular edema (ME). Intravitreal injection has proven to be an effective and safe method of drug delivery for the treatment of RVO-associated ME. With the advancement of medical science, an increasing number of medications are being utilized for intravitreal injections to address this condition, primarily glucocorticoids and anti-VEGF (vascular endothelial growth factor) agents. Glucocorticoids include triamcinolone acetonide, dexamethasone, and fluocinolone acetonide, while anti-VEGF drugs comprise ranibizumab, bevacizumab, aflibercept, and conbercept, among others. This article will provide a comprehensive review of the therapeutic progress of these medications in RVO-ME for reference in medical practice.

关 键 词：视网膜静脉阻塞 黄斑水肿 糖皮质激素 抗VEGF药 

分 类 号：R73[医药卫生—肿瘤]